Market forces push uniQure to abandon Glybera – BioPharma Dive
|
Market forces push uniQure to abandon Glybera
BioPharma Dive UniQure announced quietly on Thursday morning that it would not renew the marketing authorization of its gene therapy Glybera (alipogene tiparvovec) in Europe. In October 2012, the European Commission granted the drug a five-year marketing … |
